-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Transfer from Clinical data from Phase 1 clinical trial of Novavax's COVID-19 candidate vaccine NVX-CoV2373, published September 2 in the New England Journal of Medicine. The vaccine candidate, used in healthy adults aged 18-59, showed reassuring safety and reactive primary characteristics, and induced neutral antibody titration up to 4 times that of patients with recovery-period COVID-19.
phase 1 trial results summary: different doses of NVX-CoV2373 vaccine, placebo subjects and patients in the rehabilitation period of the mesothropic antibody titration (Human Convalescent Serum, rehabilitation patient serum; Asymptomatic, Asymptomatic patients; Patients with asymptomatic symptoms; Hospitalized, hospitalized patients; Photo: Reference: Reference: NVX-CoV2373 is based on the gene sequence of the new coronavirus (GenBank accession number, MN908947; nucleotides 21563-25384) modified candidate vaccines.
it is produced using Novavax's recombinant nanoparticle technology to produce antigens for the new coronavirus pyrethroid protein.
It also contains Novavax's proprietary saponin-based Matrix-M advent, which enhances the immune response and stimulates high levels of mesothetic antibody production by stimulating antigen delivery cells to enter the injection site and enhancing antigen delivery in the local lymph nodes.
in preclinical trials, NVX-CoV2373 demonstrated that it can block the binding of prickly proteins to viral targeted receptors, which is a key to effective protection for vaccines.
NVX-CoV2373 is currently in phase 2 clinical trials, and Phase 2 of the Phase 1/2 clinical trial to assess the safety and immunogenicity of NVX-CoV2373 began in august in the United States and Australia, expanding the phase 1 age range to include people aged 60-84 in the trial population.
: s1. Novavax Announces Publications of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine NVX-CoV2373 was generally well-well-of-the-future and elicited robust antibody responses numerically superior to see that in human convalescent sera. Retrieved September 2, 2020, from Keech, et al., (2020). Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med, DOI: 10.1056/NEJMoa2026920 follow medicinalcond.com WeChat Public No
